Conestoga Capital Advisors LLC trimmed its position in shares of Alpha Teknova, Inc. (NASDAQ:TKNO – Free Report) by 32.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 305,129 shares of the company’s stock after selling 148,770 shares during the period. Conestoga Capital Advisors LLC owned 0.57% of Alpha Teknova worth $1,477,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Roubaix Capital LLC acquired a new position in shares of Alpha Teknova during the 3rd quarter worth about $2,015,000. FourWorld Capital Management LLC acquired a new stake in shares of Alpha Teknova in the first quarter valued at approximately $135,000. Redmile Group LLC boosted its stake in shares of Alpha Teknova by 6.5% during the 1st quarter. Redmile Group LLC now owns 171,453 shares of the company’s stock worth $434,000 after acquiring an additional 10,448 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Alpha Teknova during the 1st quarter worth approximately $35,000. 13.81% of the stock is owned by institutional investors.
Alpha Teknova Price Performance
Shares of TKNO traded up $0.45 during trading hours on Friday, hitting $7.25. 38,176 shares of the company were exchanged, compared to its average volume of 222,806. The company has a quick ratio of 3.28, a current ratio of 4.76 and a debt-to-equity ratio of 0.16. Alpha Teknova, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $7.49. The company has a market cap of $386.43 million, a price-to-earnings ratio of -7.68 and a beta of 0.43. The firm’s fifty day moving average is $5.28 and its 200 day moving average is $3.31.
Analysts Set New Price Targets
Separately, Stephens reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Alpha Teknova in a research report on Wednesday, July 10th.
Read Our Latest Analysis on TKNO
Alpha Teknova Company Profile
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
See Also
- Five stocks we like better than Alpha Teknova
- Stock Market Upgrades: What Are They?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- How to Plot Fibonacci Price Inflection Levels
- Top Nuclear Stocks Thriving on Soaring Energy Demand
- What Are Dividend Achievers? An Introduction
- Apple Earnings – When Really Good Just Isn’t Good Enough
Want to see what other hedge funds are holding TKNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Teknova, Inc. (NASDAQ:TKNO – Free Report).
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.